Ghiasvand R(2026) High-Risk Stage II Melanoma: AJCC Staging anomaly or understaging dilemma? Br J Dermatol(in press) DOI 10.1093/bjd/ljaf523, PubMed 41483011
Askeland FB, Bugge VH, Rasmussen AM, Lysén A, Haukås E, Moksnes M, Eilertsen AL, Tsykunova G, Eiken BD, Leknes NM, Rolke J, Stavseth V, Samstad E, Hallstensen RF, Szatkowski D, Hansen AA, Nilsen AS, Slørdahl TS, Abdollahi P, Schjesvold F(2025) Optimizing lenalidomide therapy in renal impairment: analysis of renal response in the prospective REMNANT study in transplant-eligible newly diagnosed multiple myeloma Blood Cancer J, 15(1), 214 DOI 10.1038/s41408-025-01407-5, PubMed 41429779
Unal B, Saatcioglu F(2025) Targeting the unfolded protein response for cancer therapy: mitigating tumor adaptation and immune suppression Biomark Res, 13(1), 156 DOI 10.1186/s40364-025-00813-y, PubMed 41372991
